G/TBT/N/CAN/466  
 
17 August 2015  
(15-4179)  Page: 1/2  
Committee on Technical Barriers to Trade  Original: English/French  
 
  NOTIFICATION 
The following notification is being circulated in accordance with Article 10.6 
 
1. Notifying Member: CANADA 
If applicable, name of local government involved (Article 3.2 and 7.2):  
2. Agency responsible: Health Canada 
Name and address (including telephon e and fax numbers, email and website 
addresses, if available) of agency or authority designated to handle comments 
regarding the notification shall be indicated if different from above : 
Canada's Notification Authority and Enquiry Point 
Foreign Affairs, Trade and Development Canada 
Technical Barriers and Regulations Division (TIB) 111 Sussex Drive Ottawa, ON K1A 0G2 
Canada 
Telephone: (343)203-4273 Fax: (613)943-0346 
Email: enquirypoint@international.gc.ca  
3. Notified under Article 2.9.2 [X], 2.10 .1 [ ], 5.6.2 [ ], 5.7.1 [ ], other: 
4. Products covered (HS or CCCN where applic able, otherwise national tariff heading. 
ICS numbers may be provided in  addition, where applicable): AH-7921, its salts, 
isomers and salts of isomers and MT-45, its salts, derivatives, isomers and analogues and 
salts of derivatives, isomers and analogues (ICS: 11.120) 
5. Title, number of pages and language(s) of the notified document: Notice to 
interested parties – Proposal regarding the scheduling of AH-7921 and MT-45 under the 
Controlled Drugs and Substances Act and its Regulations (2 pages, available in English and French) 
6. Description of content: In March 2015, the United Nations Commission on Narcotic Drugs 
voted in favour of controlling AH-7921, a synthetic opioid, under Schedule I of the Single 
Convention on Narcotic Drugs , 1961 (1961 Convention). As a signatory, Canada has an 
obligation to adopt the controls required by the 1961 Convention. As structurally-related substances to AH-7921 are also known to have abuse potential and are included in the 
Convention, the salts, isomers and salts of isomers of AH-7921 will also be scheduled 
along with the parent substance.  
MT-45 is a synthetic opioid with potential health risks similar to those of other controlled 
opioids. In order to capture substances that are structurally related to MT-45 with known 
psychoactive effects, it is proposed that the salts, derivatives, isomers and analogues of 
MT-45 and the salts of these substances be scheduled along with the parent substance. 
7. Objective and rationale, including the nature of urgent problems where 
applicable: The purpose of these amendments is to protect public health and public safety  G/TBT/N/CAN/466 
 
- 2 - 
 
  8. Relevant documents: Canada Gazette , Part I, 1 August 2015, pages 2156–2157 
(available in English and French) 
9. Proposed date of adoption: Anticipated for winter 2016 
Proposed date of entry into force: On the date the regulations are adopted   
10. Final date for comments: 8 October 2015  
11. Texts available from: Nati onal enquiry point [X] or address, telephone and fax 
numbers and email and website addresses, if available, of other body:  
The electronic version of the Notice to Interested Parties can be downloaded at: http://www.gazette.gc.c a/rp-pr/p1/2015/2015-08 -01/pdf/g1-14931.pdf 
http://www.gazette.gc .ca/rp-pr/p1/2015/201 5-08-01/html/notice -avis-eng.html#nb3  
http://www.gazette.gc .ca/rp-pr/p1/2015/201 5-08-01/html/notice -avis-eng.html#nb3